CYTK insider transaction filings
CYTOKINETICS INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-15. Screen CYTK transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 25 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 21 legs across 19 filings by 6 insiders — 245,902 shares, $18,579,201 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 59.
- Largest priced transaction: sale of 97,926 shares @ $69.33 ($6,789,210) by Blum Robert I, filed 2026-09-15.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Blum Robert I — President & CEO, Director | 6 | — | 8 legs · 142,926 sh · $10,301,085 | 13 |
| Lee Sung — EVP, Chief Financial Officer | 3 | — | 3 legs · 42,976 sh · $3,551,491 | 26 |
| Callos Andrew — EVP, Chief Commercial Officer | 3 | — | 3 legs · 39,000 sh · $3,107,720 | 6 |
| Malik Fady Ibraham — EVP Research & Development | 4 | — | 4 legs · 14,000 sh · $1,114,715 | 8 |
| PARSHALL B LYNNE — Director | 1 | — | 1 leg · 5,000 sh · $357,400 | — |
| Landry Robert E — Director | 2 | — | 2 legs · 2,000 sh · $146,790 | — |
| Daly James M — Director | 1 | — | — | 1 |
| HENDERSON JOHN T — Director | 1 | — | — | 1 |
| Harrington Robert Arthur — Director | 1 | — | — | 1 |
| Kaye Edward M. MD — Director | 1 | — | — | 1 |
+2 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — CYTOKINETICS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | Landry Robert E — Director | Sale (S): 1,000 @ $72.13 | EDGAR |
| 2026-09-15 | 4 | Blum Robert I — President & CEO, Director | Option exercise (M): 7,500 @ $10.60 · Sale (S): 7,500 @ $73.44 · Gift (G): 1,350 @ $0 · Gift (G): 97,926 @ $0 · Gift (G): 97,926 @ $0 · Sale (S): 97,926 @ $69.33 · +1 more | EDGAR |
| 2026-09-11 | 4 | Landry Robert E — Director | Sale (S): 1,000 @ $74.66 | EDGAR |
| 2026-09-08 | 4 | Malik Fady Ibraham — EVP Research & Development | Option exercise (M): 3,500 @ $7.80 · Sale (S): 3,500 @ $75.46 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | PARSHALL B LYNNE — Director | Sale (S): 5,000 @ $71.48 | EDGAR |
| 2026-08-31 | 4 | Blum Robert I — President & CEO, Director | Option exercise (M): 7,500 @ $10.60 · Sale (S): 7,500 @ $70.24 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-31 | 4 | Callos Andrew — EVP, Chief Commercial Officer | Option exercise (M): 10,000 @ $23.26 · Sale (S): 10,000 @ $70.24 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-08-18 | 4 | Malik Fady Ibraham — EVP Research & Development | Option exercise (M): 3,500 @ $7.80 · Sale (S): 3,500 @ $75.82 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Blum Robert I — President & CEO, Director | Option exercise (M): 7,500 @ $10.60 · Sale (S): 7,500 @ $76.76 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Callos Andrew — EVP, Chief Commercial Officer | Option exercise (M): 14,000 @ $23.26 · Sale (S): 14,000 @ $79.88 · Option exercise (M): 14,000 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Blum Robert I — President & CEO, Director | Option exercise (M): 7,500 @ $10.60 · Sale (S): 7,500 @ $80.87 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-07-23 | 4 | Malik Fady Ibraham — EVP Research & Development | Option exercise (M): 3,500 @ $7.80 · Sale (S): 3,500 @ $80.59 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | Wysenski Nancy — Director | Grant/award (A): 75 @ $82.62 | EDGAR |
| 2026-07-16 | 4 | WIERENGA WENDELL — Director | Grant/award (A): 75 @ $82.62 | EDGAR |
| 2026-07-16 | 4 | Kaye Edward M. MD — Director | Grant/award (A): 151 @ $82.62 | EDGAR |
| 2026-07-16 | 4 | HENDERSON JOHN T — Director | Grant/award (A): 272 @ $82.62 | EDGAR |
| 2026-07-16 | 4 | Harrington Robert Arthur — Director | Grant/award (A): 151 @ $82.62 | EDGAR |
| 2026-07-16 | 4 | Daly James M — Director | Grant/award (A): 151 @ $82.62 | EDGAR |
| 2026-07-14 | 4 | Blum Robert I — President & CEO, Director | Sale (S): 10 @ $82.02 · Option exercise (M): 7,490 @ $10.60 · Sale (S): 7,490 @ $82.02 · Option exercise (M): 7,490 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Malik Fady Ibraham — EVP Research & Development | Option exercise (M): 3,500 @ $7.80 · Sale (S): 3,500 @ $86.62 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Blum Robert I — President & CEO, Director | Sale (S): 7,500 @ $84.92 | EDGAR |
| 2026-07-02 | 4 | Callos Andrew — EVP, Chief Commercial Officer | Option exercise (M): 15,000 @ $23.26 · Sale (S): 15,000 @ $85.80 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Lee Sung — EVP, Chief Financial Officer | Option exercise (M): 1,112 @ $48.51 · Sale (S): 1,112 @ $87.79 · Option exercise (M): 1,112 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Lee Sung — EVP, Chief Financial Officer | Option exercise (M): 23,370 @ $48.51 · Option exercise (M): 9,307 @ $44.36 · Option exercise (M): 2,817 @ $44.36 · Option exercise (M): 1,113 @ $48.51 · Option exercise (M): 188 @ $44.36 · Option exercise (M): 822 @ $44.36 · +9 more | EDGAR |
| 2026-06-29 | 4 | Lee Sung — EVP, Chief Financial Officer | Option exercise (M): 188 @ $44.36 · Option exercise (M): 822 @ $44.36 · Option exercise (M): 1,113 @ $48.51 · Option exercise (M): 188 @ $44.36 · Option exercise (M): 823 @ $44.36 · Sale (S): 3,134 @ $85 · +5 more | EDGAR |
| 2026-06-23 | 4 | Malik Fady Ibraham — EVP Research & Development | Option exercise (M): 3,500 @ $7.80 · Sale (S): 3,500 @ $79.51 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Blum Robert I — President & CEO, Director | Sale (S): 7,500 @ $70.46 | EDGAR |
| 2026-06-09 | 4 | Malik Fady Ibraham — EVP Research & Development | Option exercise (M): 3,500 @ $7.80 · Sale (S): 3,500 @ $67.98 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Kaye Edward M. MD — Director | Sale (S): 2,933 @ $76.09 | EDGAR |
| 2026-06-01 | 4 | Callos Andrew — EVP, Chief Commercial Officer | Option exercise (M): 15,000 @ $23.26 · Sale (S): 15,000 @ $74.08 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | PARSHALL B LYNNE — Director | Sale (S): 5,000 @ $74.08 | EDGAR |
| 2026-05-28 | 4 | Blum Robert I — President & CEO, Director | Sale (S): 7,500 @ $77.21 | EDGAR |
| 2026-05-27 | 4 | Bhanji Muna — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Daly James M — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Harrington Robert Arthur — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | HENDERSON JOHN T — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Kaye Edward M. MD — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | PARSHALL B LYNNE — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Landry Robert E — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | WIERENGA WENDELL — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Wysenski Nancy — Director | Grant/award (A): 2,851 @ $0 · Grant/award (A): 4,301 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Malik Fady Ibraham — EVP Research & Development | Option exercise (M): 3,500 @ $7.80 · Sale (S): 3,500 @ $75.69 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Blum Robert I — President & CEO, Director | Sale (S): 7,500 @ $77.92 | EDGAR |
| 2026-05-05 | 4 | Malik Fady Ibraham — EVP Research & Development | Option exercise (M): 3,500 @ $7.80 · Sale (S): 3,500 @ $77.37 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | WIERENGA WENDELL — Director | Option exercise (M): 4,032 @ $12.40 · Sale (S): 4,032 @ $75 · Option exercise (M): 4,032 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Lee Sung — EVP, Chief Financial Officer | Sale (S): 23,906 @ $76.87 | EDGAR |
| 2026-05-05 | 4 | HENDERSON JOHN T — Director | Option exercise (M): 20,000 @ $7.61 · Sale (S): 20,000 @ $75.97 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Callos Andrew — EVP, Chief Commercial Officer | Option exercise (M): 11,333 @ $39.13 · Sale (S): 11,333 @ $77.25 · Option exercise (M): 11,333 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Callos Andrew — EVP, Chief Commercial Officer | Option exercise (M): 15,857 @ $37.63 · Sale (S): 15,857 @ $65 · Option exercise (M): 15,857 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Callos Andrew — EVP, Chief Commercial Officer | Option exercise (M): 15,000 @ $23.26 · Sale (S): 15,000 @ $63.26 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — CYTOKINETICS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-19 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CYTK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →